On May 13, 2020, the FDA approved Fluad Quadrivalent (influenza vaccine, adjuvanted; Seqirus) for adults 65 years and older. FLUAD QUADRIVALENT (aQIV) utilizes the same MF59ﾮ adjuvant technology as FLUADﾮ (aTIV), designed to create a strong, broad and durable immune response. FLUAD QUADRIVALENT includes an additional strain to FLUAD, which has an extensive clinical legacy, with 114+ million doses distributed and licensure in 29 countries since it was first approved in 1997 in Italy and the U.S. in 2015.